To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare.

Repeal Medicare Sustainable Growth Rate formula; Monitor implementation, P.L. 111-148; Extend Section 3111, P.L. 111-148; H.R. 4015 / S. 2000, SGR Repeal and Medicare Provider Payment Modernization Act; H.R. 2810, Medicare Patient Access and Quality Improvement Act of 2013; S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013; H.R. 4302, Protecting Access to Medicare Act; H.R. 1416, Cancer Patient Protection Act; H.R. 2305 / S. 1123, Preventing and Reducing Improper Medicare and Medicaid Expenditures Act; H.R. 5481, To continue the use of a 3-month quarter EHR reporting period for health care providers to demonstrate meaningful use for 2015 under EHR incentive payment programs; H.R. 800, To exclude prompt pay discounts from ASP formula

Client expense: $100,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding and Reimbursement Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1416, Cancer Patient Protection Act of 2013 H.R. 4302, Protecting Access to Medicare Act of 2014 21st Century Cures Initiatives

Client expense: $370,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act. H.R. 2869 "Medicare Patient Access to Cancer Treatment Act of 2013" H R 4302 "Protecting Access to Medicare Act of 2014" (PL 113-93) S.806/H.R.800 "To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare"

Client expense: $338,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 806, H.R. 800 & H.R. 1416 relating to Average Sales Price

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare Part B Monitored CY13 & 14 Physician Fee Schedule for Neurologists Monitored Prompt Pay Legislation, H.R. 800 & S. 806 Monitored Implementation of the Medicare IVIG Access Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

**see addendum pageAverage Sales Price (H.R. 800, H.R. 1416, S. 806) PPACA Implementation (PL 111-148) SGR (H.R. 2810, S. 1871) Centers For Medicare and Medicaid Services (Sunshine, AMP and NADAC)

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 8; H.R. 800; S. 806; H.R.1416; H.R. 4709

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: $570,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R.800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R.1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R.4709, S.1277, S.1657, H.R.3392, H.R.4096 & S. 2862 legislation to prevent and reduce prescription drug abuse. H.R. 4190, Provide for coverage under Medicare program of pharmicist services

Client expense: $570,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

- Issues related to Medicare reimbursement for Clinical Laboratory Services. - HR 8, "American Taxpayer Relief Act of 2012", regarding all provisions in Section 636. - HR 800, "To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare", regarding all provisions.- Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues related to implantable medical devices. - Issues related to diabetes care products. - Issues related to competitive bidding of diabetes care products. - Issues related to health care pricing transparency. - Issues related to OIG study regarding competitive bidding. - Issues related to the CMS proposed rule regarding Medicare Part D and 6 protected classes. - S 1871, "SGR Repeal and Medicare Beneficiary Access Act of 2013", regarding all provisions. - PL 111-148, "Patient Protection and Affordable Care Act", regarding provisons related to the sustainable growth rate. - Issues related to 340B payments to hospitals. - HR 5644/ S 2689, "Medicare CGM Access Act of 2014", regarding all provisions. - HR 4302/ PL 113-93, "Protecting Access to Medicare Act of 2014", regarding implementation.

Client expense: $1,400,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

(H.R.800/S. 806) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction). Sustainable Growth Rate.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.800 & S.806 Medicare Prompt Pay Discount Exclusion (H.R.800 & S.806), legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Cancer Patient Protection Act of 2013 (H.R.1416), legislation to exclude cancer drugs from sequestration cuts. Prescription Drug Abuse Legislation (H.R.1919, H.R.3204, S.957 & S.959)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; health information technology; application of the sequester to cancer drug reimbursement (HR 1416 - the Cancer Patient Protection Act of 2013); prompt pay discount (HR 800 Prompt Pay Discount Legislation); safety and security of the prescription drug supply chain. Oncology payment disparities in Medicare (HR 2869)

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 800, H.R. 1416, S.806); PPACA Implementation (PL 111-148); Sustainable Growth Rate (S. 1871 and H.R. 2810); Centers for Medicare and Medicaid Services (Sunshine, AMP and NADAC)

Client expense: $257,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Cancer Patient Protection Act of 2013 (HR 1425) to stop the Medicare sequester cut from being applied to payment for cancer drugs. Correcting a technical problem with Medicare reimbursement for cancer drugs (inclusion of wholesaler-to-manufacturer prompt pay discounts in the calculation of Medicare ASP-based reimbursement rates) (HR800 & S806). General fix to the Medicare SGR-based physician reimbursement system. Payment reform for cancer care. Problems with the 340B drug discount program. Payment parity between community cancer clinics and outpatient hospital departments.

Client expense: $82,085 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Medicare Part B Monitored CY13 & 14 Physician Fee Schedule for Neurologists Monitored Prompt Pay Legislation, H.R. 800 & S. 806 Monitored Implementation of the Medicare IVIG Access Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800, prompt pay legislation; health IT and meaningful use; radiation and reimbursement issues; SGR Medicare physician payments; H.R.1416 Cancer Patient Protection Act of 2013; H.R. 2869, Medicare Patient Access to Cancer Treatment Act of 2013

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Repeal Sustainable Growth Rate formula; Monitor implementation, P.L. 111-148; Extend Section 3111, P.L. 111-148; H.R. 4015 / S. 2000, SGR Repeal and Medicare Provider Payment Modernization Act; S. 1871, SGR Repeal and Medicare Beneficiary Access Act of 2013; H.R. 1416, Cancer Patient Protection Act; H.R. 2305 / S. 1123, Preventing and Reducing Improper Medicare and Medicaid Expenditures Act; H.R. 2810, Medicare Patient Access and Quality Improvement Act; H.R. 4302, Protecting Access to Medicare Act; H.R. 5481, To continue the use of a 3-month quarter EHR reporting period for health care providers to demonstrate meaningful use for 2015 under EHR incentive payment programs; H.R. 800, To exclude prompt pay discounts from ASP formula

Client expense: $120,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

HR800/S806 - Amends part B (Supplementary Medical Insurance) of title XVIII (Medicare) of the Social Security Act to exclude from the average sales price in calculating Medicare payments for drugs and biologicals any customary prompt pay discounts from manufacturers to wholesalers. HR2869 - To amend title XVIII of the Social Security Act to establish payment parity under the Medicare program for ambulatory cancer care services furnished in the hospital outpatient department and the physician office setting. Opposition to proposed Medicare cuts to radiation oncology services due to removal of radiation treatment vault as a direct practice expense input. No specific legislation.

Client expense: Not reported · Firm income: $13,500

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure ore appropriate general payment amount for drugs and biological under Part B of the Medicare program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care. HR 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. HR 1416 Cancer Patient Protection Act of 2013, legislation to exclude cancer drugs from sequestration cuts. HR 1919, HR 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Sequestration cuts to cancer care. H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

ESRD "Bundling Issues" and ESRD Drug Reimbursement Issues HCPCS Coding Decisions Implementation of P.L. 111-148, Patient Protection & Affordable Health Care Act Least Costly Alternative PolicyChanges re: Medicare Part B and Average Sales Price Medicare Secondary Payor for ESRD Services Extension of Rebates on Medicare Part D Drugs Performance Measures for Bone and Mineral Metabolism for ESRD Program 340B Issues Implementation of American Taxpayer Relief Act of 2012 H.R. 413, to eliminate two-year delay including oral-only ESRD-related drugs in the Medicate ESRD prospective payment system S. 77, Prescription Drug and Health Improvement Act of 2013 S. 117, Medicare Prescription Drug Price Negotiation Act of 2013 H.R. 800, to exclude prompt pay discounts from the average sales price for drugs and biologics under Medicare Part B H.R. 1516, Cancer Patient Protection Act of 2013 H.R. 4302, Protecting Access to Medicare Act of 2014 21st Century Cures Initiatives

Client expense: $330,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Physician and pharmacy reimbursement issues. Implementation of the Affordable Care Act. H.R. 2869 "Medicare Patient Access to Cancer Treatment Act of 2013" H R 4302 "Protecting Access to Medicare Act of 2014" (PL 113-93) H.R. 1416 "Cancer Patient Protection Act of 2013"S.806/H.R.800 "To amend Part B of title XVII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biological under Medicare"

Client expense: $240,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

(H.R.800/S. 806) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price (ASP) generally (in the context of deficit reduction). Sustainable Growth Rate.

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.800 & S.806 Medicare Prompt Pay Discount Exclusion (H.R.800 & S.806), legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Cancer Patient Protection Act of 2013 (H.R.1416), legislation to exclude cancer drugs from sequestration cuts. Prescription Drug Abuse Legislation (H.R.1919, H.R.3204, S.957 & S.959)

Client expense: Not reported · Firm income: $30,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare Part B Monitored CY13 & 14 Physician Fee Schedule for Neurologists Monitored Prompt Pay Legislation, H.R. 800 & S. 806 Monitored Implementation of the Medicare IVIG Access Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.800 & S.806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. H.R.1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R.4709, S.1277, S.1657, H.R.3392, H.R.4096 & S. 2862 legislation to prevent and reduce prescription drug abuse. H.R. 4190, Provide for coverage under Medicare program of pharmicist services

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) Generally (in the context of Deficit Reduction). Oncology Innovation Project - Center for Medicare and Medicaid Innovation. Sequestration cuts to cancer care.H.R. 1416 (Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

Implementation of the Patient Protection and Affordable Care Act; issues related to Medicare drug reimbursement; H.R. 8; H.R. 800; S. 806; H.R.1416; H.R. 4709

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Average Sales Price (H.R. 800, H.R. 1416, S. 806); PPACA Implementation (PL 111-148);Sustainable Growth Rate (S. 1871 and H.R. 2810); Centers for Medicare and Medicaid Services (Sunshine, AMP and NADAC); The Protecting Access to Medicare Act of 2014 (H.R. 4302)

Client expense: $361,413 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Average Sales Price (H.R. 800, H.R. 1416, S. 806); PPACA Implementation (PL 111-148);Sustainable Growth Rate (S. 1871 and H.R. 2810); Centers for Medicare and Medicaid Services (Sunshine, AMP and NADAC); The Protecting Access to Medicare Act of 2014 (H.R. 4302)

Client expense: $361,413 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

- Issues related to Medicare reimbursement for Clinical Laboratory Services. - HR 8, "American Taxpayer Relief Act of 2012", regarding all provisions in Section 636. - HR 800, "To amend part B of title XVIII of the Social Security Act to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare", regarding all provisions.- Issues related to physician-owned companies that manufacture or distribute medical devices. - Issues related to implantable medical devices. - Issues related to diabetes care products. - Issues related to competitive bidding of diabetes care products. - Issues related to health care pricing transparency. - Issues related to OIG study regarding competitive bidding. - Issues related to the CMS proposed rule regarding Medicare Part D and 6 protected classes. - S 1871, "SGR Repeal and Medicare Beneficiary Access Act of 2013", regarding all provisions. - PL 111-148, "Patient Protection and Affordable Care Act", regarding provisons related to the sustainable growth rate. - Issues related to 340B payments to hospitals. - HR 5644/ S 2689, "Medicare CGM Access Act of 2014", regarding all provisions. - HR 4302/ PL 113-93, "Protecting Access to Medicare Act of 2014", regarding implementation.

Client expense: $1,350,000 · Firm income: Not reported

Government targets: Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)

The Ensuring Patient Access and Effective Drug Enforcement Act (H.R. 4069/S. 2862); Average Sales Price calculation/prompt pay discount (H.R. 800); Tax (Last in, first out)

Client expense: Not reported · Firm income: Not reported

The Ensuring Patient Access and Effective Drug Enforcement Act (H.R. 4069/S. 2862); Average Sales Price calculation/prompt pay discount (H.R. 800); Tax (Last in, first out)

Client expense: Not reported · Firm income: Not reported

**see addendum pageAverage Sales Price (H.R. 800, H.R. 1416, S. 806) PPACA Implementation (PL 111-148) SGR (H.R. 2810, S. 1871) Protecting Access to Medicare Act of 2014 (H.R. 4302) Centers For Medicare and Medicaid Services (Sunshine, AMP and NADAC)

Client expense: Not reported · Firm income: $80,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

S. 806, H.R. 800 & H.R. 1416 relating to Average Sales Price

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare, oncology, Radiation and Imaging Reimbursement issues; medicare physician payments; Health Information Technology; application of the sequester to cancer drug reimbursement (H.R.1416, the Cancer Patient Protection Act of 2013); prompt pay discount (HR 800 Prompt Pay Discount Legislation); safety and security of the prescription drug supply chain

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

pharmaceutical and health care product distribution issues, Medicare Part B and D issues, Medicaid pharmacy issues, HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014.

Client expense: Not reported · Firm income: $15,000

HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014

Client expense: Not reported · Firm income: $15,000

HR 800, S. 806, HR 4709, Ensuring Patient Access and Effective Drug Enforcement Act of 2014

Client expense: Not reported · Firm income: $7,500